Company Filing History:
1 out of 112 
1 out of 5,111 
1 out of 4 Years Active: 2019
Title: Fabrice Journe: Innovator in Melanoma Research
Introduction
Fabrice Journe is a notable inventor based in Blaregnies, Belgium. He has made significant contributions to the field of melanoma research, particularly through his innovative approaches to treatment and patient management.
Latest Patents
Fabrice Journe holds a patent for TYRP1, a natural miRNA sponge, and its use in managing human melanoma aggressiveness. This invention relates to methods and reagents for the treatment of melanoma and metastatic melanoma that directly or indirectly target the TYRP1 RNA transcript. Additionally, it includes methods for predicting a melanoma patient's therapeutic responsiveness and assessing the effectiveness of such treatments. The invention also introduces a combination of biological markers that can predict melanoma patients' survival, regardless of the treatment administered. He has 1 patent to his name.
Career Highlights
Throughout his career, Fabrice Journe has worked with esteemed institutions such as Université de Rennes 1 and the Centre National de la Recherche Scientifique. His work has been pivotal in advancing the understanding and treatment of melanoma.
Collaborations
Fabrice has collaborated with notable colleagues, including David Gilot and Marie-Dominique Galibert. Their joint efforts have contributed to the progress in melanoma research and treatment methodologies.
Conclusion
Fabrice Journe's innovative work in melanoma research exemplifies the impact of dedicated inventors in the medical field. His contributions continue to influence the treatment and management of this aggressive form of cancer.